No. patients evaluable for occurrence of late complications subdivided according to interval from transplantation to development of sequelae
| Follow-up interval, mo . | No. patients evaluable . | Late effect . | ||
|---|---|---|---|---|
| No . | Yes (%) . | Specifics . | ||
| 18-24 | 44 | 19 | 3 (14) | 3 thyroid abnormalities |
| 24-36 | 22 | 18 | 4 (18) | 3 thyroid abnormalities |
| 1 growth impairment | ||||
| 36-48 | 19 | 16 | 3 (16) | 1 thyroid abnormality |
| 1 chronic pulmonary insufficiency | ||||
| 1 early puberty | ||||
| 48-60 | 10 | 3 | 7 (70) | 3 growth impairment |
| 1 growth impairment + hypogonadism | ||||
| 1 amenorrhea | ||||
| 1 delayed puberty | ||||
| 1 mild impairment of pulmonary function | ||||
| 60-72 | 20 | 12 | 8 (40) | 1 growth impairment |
| 2 growth impairment + thyroid abnormality | ||||
| 2 thyroid abnormality | ||||
| 1 early puberty | ||||
| 2 hypogonadism | ||||
| 72-84 | 10 | 3 | 7 (70) | 2 growth impairment |
| 1 growth impairment + thyroid abnormality | ||||
| 1 thyroid abnormality | ||||
| 2 hypogonadism (1 with osteopenia) | ||||
| 1 mental retardation | ||||
| 84-96 | 8 | 4 | 4 (50) | 1 growth impairment |
| 2 thyroid abnormality | ||||
| 1 growth impairment + thyroid abnormality + cataract | ||||
| 96-108 | 8 | 6 | 2 (25) | 1 growth impairment |
| 1 growth impairment + hypogonadism + arthritis | ||||
| 108-120 | 10 | 7 | 3 (30) | 1 growth impairment |
| 1 growth impairment + thyroid abnormality + cataract | ||||
| 1 thyroid abnormality + ovarian failure | ||||
| more than 120 | 18 | 10 | 8 (44) | 3 growth impairment |
| 1 thyroid abnormality | ||||
| 1 impairment of cardiac function + ovarian failure + hepatitis C | ||||
| 1 growth impairment + thyroid abnormality + ovarian failure + NIDDM + hepatitis C | ||||
| 2 hypogonadism | ||||
| Total no. patients evaluable | 169 | 98 | 49 | |
| Follow-up interval, mo . | No. patients evaluable . | Late effect . | ||
|---|---|---|---|---|
| No . | Yes (%) . | Specifics . | ||
| 18-24 | 44 | 19 | 3 (14) | 3 thyroid abnormalities |
| 24-36 | 22 | 18 | 4 (18) | 3 thyroid abnormalities |
| 1 growth impairment | ||||
| 36-48 | 19 | 16 | 3 (16) | 1 thyroid abnormality |
| 1 chronic pulmonary insufficiency | ||||
| 1 early puberty | ||||
| 48-60 | 10 | 3 | 7 (70) | 3 growth impairment |
| 1 growth impairment + hypogonadism | ||||
| 1 amenorrhea | ||||
| 1 delayed puberty | ||||
| 1 mild impairment of pulmonary function | ||||
| 60-72 | 20 | 12 | 8 (40) | 1 growth impairment |
| 2 growth impairment + thyroid abnormality | ||||
| 2 thyroid abnormality | ||||
| 1 early puberty | ||||
| 2 hypogonadism | ||||
| 72-84 | 10 | 3 | 7 (70) | 2 growth impairment |
| 1 growth impairment + thyroid abnormality | ||||
| 1 thyroid abnormality | ||||
| 2 hypogonadism (1 with osteopenia) | ||||
| 1 mental retardation | ||||
| 84-96 | 8 | 4 | 4 (50) | 1 growth impairment |
| 2 thyroid abnormality | ||||
| 1 growth impairment + thyroid abnormality + cataract | ||||
| 96-108 | 8 | 6 | 2 (25) | 1 growth impairment |
| 1 growth impairment + hypogonadism + arthritis | ||||
| 108-120 | 10 | 7 | 3 (30) | 1 growth impairment |
| 1 growth impairment + thyroid abnormality + cataract | ||||
| 1 thyroid abnormality + ovarian failure | ||||
| more than 120 | 18 | 10 | 8 (44) | 3 growth impairment |
| 1 thyroid abnormality | ||||
| 1 impairment of cardiac function + ovarian failure + hepatitis C | ||||
| 1 growth impairment + thyroid abnormality + ovarian failure + NIDDM + hepatitis C | ||||
| 2 hypogonadism | ||||
| Total no. patients evaluable | 169 | 98 | 49 | |
NIDDM indicates non–insulin-dependent diabetes mellitus.